• info@cancerinformation.com.hk
  • 2121 1328
  • facebook


文章 | 醫療新知 | 國際視野 / 癌症資訊網編輯室
頁數 [1] 2 3

癌症資訊網編輯室

維省綜合癌症中心(Victorian Comprehensive Cancer Centre)。(資料圖片)   癌症研究與治療的發展,在全球備受關注,李嘉誠基金會將捐出300萬美元(約2,300萬港元)予澳洲墨爾本大學癌症研究中心(University of Melbourne Centre for Cancer Research,簡稱UMCCR),支持基因腫瘤學研究,冀使用尖端科技,將癌症轉化為可控慢性疾病。 墨爾本大學是李嘉誠基金會首家捐助的澳洲大學,UMCCR的基因腫瘤學研究,世界首屈一指。UMCCR亦是澳洲最大癌症研究與治療機構、世界一流水平的維省綜合癌症中心(Victorian Comprehensive Cancer Centre)的基本合作夥伴,雙方會組成龐大的臨床和科研專家隊伍,研究具挑戰性的癌症課題。 墨爾本大學校長戴維斯(Glyn Davis)教授說:「李嘉誠基金會的慷慨捐贈將有助於推進墨爾本大學為攻克癌症難關而進行的尖端研究,並得以擴展研究知識和專業技能,幫助改善全球健康問題。」 李嘉誠先生表示:「UMCCR滙聚癌症研究精英,中心的工作深具意義,可謂人類醫學史上的里程碑。期望UMCCR成為全球癌症研究的重要樞紐,為癌症研究尋求新的突破。」 此計劃會側重對上消化道癌症的研究,旨在透過基因藥物,改進亞太地區上消化道癌症的治療效果,讓此類癌症患者免受入侵性治療而得以提高存活率。UMCCR創始主任格林蒙德(Sean Grimmond)教授表示,捐款有助他們使用精準醫學技術來治療難度極高的上消化道癌症。 有關李嘉誠基金會 李嘉誠基金會於 1980 年創立,主要專注於支持教育和醫療項目,至今捐款已逾200億港元,項目遍及全球27個國家及地區。2006年李嘉誠先生向大家闡述基金會是他第三個兒子的概念,他認為亞洲在奉獻文化上的觀念要有突破,要視建立社會的責任和延續後代同樣重要,分配財產作捐助,推動社會改善進步;這一念之悟,將為明天帶來更多新希望,世界因而更美好。
馮維維

圖片來源:SHERBROOKE CONNECTIVITY IMAGING LAB/SCIENCE PHOTO LIBRARY   寨卡病毒會導致嬰兒出生後存在嚴重腦損傷,但人們或可利用這種病毒抵抗成年人腦瘤。   寨卡病毒約在4年前從波利尼西亞到達南美洲,它在懷孕女性中尤為危險。它會導致頭小畸形(異常的小頭癥),並與母親懷孕時感染病毒的嬰兒出現神經問題存在關聯,此外還會導致更高的流產率。   寨卡病毒之所以如此,是因為它與大多數微生物不同,會從血液進入大腦,並在那裏感染及殺死幹細胞,對發育大腦造成嚴重負面影響。   但寨卡病毒影響大腦幹細胞的能力已被證實或對抵抗致命腦癌具有幫助,很多腦癌是由於幹細胞變異造成的。   美國加州大學聖疊戈分校的Jeremy Rich和團隊通過惡性膠質瘤(最常見的腦癌)測試了寨卡病毒。惡性膠質瘤是最難治愈的癌癥之一,即便在經過手術和其他治療之後,它通常還會在一年內導致病人死亡。   該團隊發現,將生長在培養皿中的惡性膠質瘤的樣本暴露給寨卡病毒之後,會損傷癌癥幹細胞。通常這些幹細胞會導致病人死亡,因為它們對所有可獲得的療法具有抵抗力。   當該團隊在未罹患癌癥的成年人的普通腦細胞上驗證寨卡病毒後,他們發現該病毒並不會影響組織,這或許可以解釋為什麼寨卡病毒鮮少在成年人中致病。   接下來,該團隊在植入惡性膠質瘤的小鼠體內驗證了該病毒。通常,這一類老鼠會在1個月內死亡,然而那些註射了寨卡病毒的小鼠生命會更長,9只小鼠中有4只小鼠在兩個月後依然存活。   Rich表示,目前尚不清楚這種機制在人體中會如何轉化,因為該疾病對小鼠的影響不同於人類。   研究人員並未計劃在患有腦癌的人中間驗證寨卡病毒,因為他們擔心它會被傳播給孕婦:美國一些區域發現了攜帶寨卡病毒的蚊蟲,該病毒可以通過性傳播。與此相對,該團隊計劃了解是否可以對該病毒進行基因編輯,使其變得更加安全,同時在研究將其作為腦癌的潛在療法。       Zika virus used to treat aggressive brain cancer By Michelle RobertsHealth editor, BBC News online   Image copyrightGETTY IMAGES A harmful virus that can cause devastating brain damage in babies could offer up a surprising new treatment for adult brain cancer, according to US scientists. Until now, Zika has been seen only as a global health threat - not a remedy. But latest research shows the virus can selectively infect and kill hard-to-treat cancerous cells in adult brains. Zika injections shrank aggressive tumours in fully grown mice, yet left other brain cells unscathed. Human trials are still a way off, but experts believe Zika virus could potentially be injected into the brain at the same time as surgery to remove life-threatening tumours, the Journal of Experimental Medicine reports. The Zika treatment appears to work on human cell samples in the lab. Image copyrightGETTY IMAGES Image captionThe virus would need to be delivered directly to where it is needed in the brain There are many different types of brain cancer. Glioblastomas are the most common in adults and one of the trickiest to treat. They are fast growing and diffuse, meaning they spread through the brain, making it difficult to see where the tumour ends and the healthy tissue begins. Radiotherapy, chemotherapy and surgery may not be enough to remove these invasive cancers. But the latest research, in living mice and donated human brain tissue samples, shows Zika therapy can kill cells that tend to be resistant to current treatments. It is thought that these glioblastoma stem cells continue to grow and divide, producing new tumour cells even after aggressive medical treatment. Different, healthy stem cells are found in abundance in baby brains, which probably explains why regular Zika can be so damaging to infants, say the researchers. Adult brains, however, have very few stem cells. This means Zika treatment should destroy only the cancer-causing brain stem cells without causing much collateral damage. As an extra safety precaution, the team, from Washington University School of Medicine and the University of California San Diego School of Medicine, have already begun modifying the virus to make it more tame than regular Zika. Researcher Dr Michael Diamond said: "Once we add a few more changes, I think it's going to be impossible for the virus to overcome them and cause disease. "It looks like there's a silver lining to Zika. This virus that targets cells that are very important for brain growth in babies, we could use that now to target growing tumours." He hopes to begin human trials within 18 months. Using viruses to fight cancer is not a new idea, but using Zika as the weapon of choice is. UK scientists at the University of Cambridge are beginning similar trials with Zika. Dr Catherine Pickworth, from Cancer Research UK, said: "This promising research shows that a modified version of the Zika virus can attack brain tumour cells in the lab. "This could one day lead to new treatments for this particularly hard to treat type of cancer." Zika Image copyrightREUTERS Image captionZika infections in pregnancy have been linked to cases of microcephaly in newborns Zika is a virus people can catch if they are bitten by an infected mosquito Most people will have few or no symptoms, but the disease can pose a serious threat to babies in the womb Affected infants have been born with abnormally small heads and underdeveloped brains - a condition known as microcephaly The infection has been linked to severe birth defects in almost 30 countries Although Zika is no longer "an international medical emergency", the World Health Organization says it is closely monitoring the infection   http://www.bbc.com/news/health-41146628  
作者:Gabri / 翻譯:張碧瑜 癌症資訊網

  2008年8月,加布里埃爾(Gabrielle)被確診患有非何傑金淋巴瘤(non-Hodgkin’s lymphoma)。腫瘤病發於其肘部,并擴散至腹股溝兩側。50歲的加布里埃爾是GTS社區的成員之一,確診患病後實現了自己的潛水夢。大家被她的無畏精神感動,為她的快樂和勇敢而感動。儘管我們素未謀面,因為海,我們連在一起。以下是加布里埃爾的故事分享: 親愛的潛水日誌,這次我贏了 這次我贏了!   我擊倒了內在的阻力,完成了一些本來自己無法主宰、無法征服的事情。   我認為放下一切,才能隨遇而安,隨緣奉獻。   首次潛水那天,我準時到達俱樂部,但是那裡比平時更擁擠。來自米蘭的一群人打亂了潛水俱樂部禮拜日早上的日常課程 : 所有學員都忙於準備第二輪湖泊潛水課程的裝備, 我們要等第一輪課程的船隻回來,但是船隻已多次來回接送米蘭學員。我的教練帶著他們,所以我仍需等待。與此同時,潛水的同學幫我找到的最佳潛水裝備:潛水衣、面鏡、蛙鞋、短靴, 我就像一個讓隨從幫忙的中世紀騎士。   我的攝影師朋友和潛水教練同時到達。上一組學員的行為顯然令教練惱火,但是他隨即對我友好親切,開始幫我準備其餘的裝備——浮力調整裝置(BCD)、配重系統、調節器、氣瓶。     “當所有的檢查要完成的時候,我開始不分日夜地思考, 我有兩個孩子,一個17歲、一個12歲。十幾歲的孩子能理解病情,但是對他們來說,這個消息太過沉重,所以在家裡我必須堅強。”     幾番指導後,我們準備出發,一個小型輪車幫我把潛水裝備從跳台轉移到船里。在風和日麗的禮拜日早上,我們終於駛入湖裡。像海邊那樣,到處都是毛巾,到處都是遊客。他們享受日光下的一天。   同行的朋友叫我把Gopro遞給他,我才發現他早已下水。教練示意我下水,朋友開始記錄我的潛水過程。   我戴上浮力調整裝置、調節器、面鏡,坐在船邊輕輕滑出去,回過神來,我已在水裡。   四周都是泡泡,我不知道身處何方,無法呼吸。出於本能,我屏住呼吸,直至回到水面。我不懂怎樣取出口裡的調節器,感覺自己是一隻笨重的企鵝。他們說第一次潛水,這種感覺很正常,我只要記住呼吸!   聽起來很可笑,但事實上,潛水並非那麼簡單。   教練說,頭浸入水中便呼吸,於是我學會呼吸,便開始緩慢下潛。教練在前,用手拉著我前進。   如果耳朵不適,捏住鼻子,用力向鼻腔內鼓氣,升高耳道內氣壓以抵消水壓,以緩和不適。這樣的確有效!我潛到水裡,發生的一切都令我難以置信! 我真的潛在水裡! 雖然有點動蕩不定,但是可以堅持一段時間。   每吸一口氣,我都看到很多氣泡。湖水湧入我的面鏡之前,我都以為這很正常。我無法完成教練的指示,不斷嘗試時,突然出錯,更多水湧入面鏡,我突然吸氣,立刻嗆水。我驚慌失措,開始咳嗽,要求立刻上升。一會兒便回到水面,夥伴們安慰我,對我說,呼氣吸氣,保持冷靜,一切安好。   我不放棄:咳嗽了幾分鐘後,但我不害怕。就算說過再也無法忍受,我仍準備再次下潛。頭朝下,我們再出發。此後,事情越來越順利,我開始見到一群小魚、一條尖嘴魚、一些淡水蝦,海底世界真美麗!水中的樹枝猶如藝術傑作,陽光錯落,光影間的樹枝如同現代雕塑。我們和其他潛水者相遇,再下潛一段距離就上岸了。   完成!感覺很奇妙!潛水是我多年的夢想,現在我在這美麗的湖泊,離家僅幾分鐘車程的地方!剛剛潛水,現在脫掉裝備,談論與夥伴們共同經歷的事情,感覺非常開心!   我突然想通了。去年夏季,被確診淋巴瘤,而今年夏季,我再次出發!什麼淋巴瘤,骨髓活檢, 覆診體檢!這統統都不能擊敗我!   今年,我贏了!   生活如此美好:在炎熱的7月,美好的禮拜日早上,我回到船里,享受著回程的每分每秒。   Ale、Renzo,謝謝你們!我很快回來!   Gabri字 (2015年7月18日)   “潛到水底,不會再想起治療、檢查、醫生、醫院等。在那裡,我孤身一人,聽自己的呼吸,驚歎這美妙的海底世界。這幅景象只有潛水才能欣賞!”   https://www.girlsthatscuba.com/2017/03/14/cancer-and-scuba-diving-gabrielle-s-story/
作者:Kathlyn / 翻譯:張碧瑜 癌症資訊網

作者:Kathlyn(HealthNewsReview.org副主編,推特號:@KatKStone)/ 翻譯:張碧瑜   過去幾天,我們密切關注全球最盛大的癌症研究會議——美國臨床腫瘤學會(ASCO)的新聞報道。今年ASCO的主題是“與你一起改進癌症護理(Making a difference in cancer care with you)”。   6月5日撤銷了針對會議中一些頗有新聞價值研究的禁令,一種兼具趣味性和激勵性的格局便立刻浮現。這種格局在與會人員和金融新聞媒體中尤為突出,他們的關注點通常是高價藥物成本和新療法的邊際效益,偏離了宣傳材料的基調。   文森特(Dr.S.Vincent Rajkumar ,梅約診所專攻血液腫瘤科的內科醫生)對ASCO 中談論的花費做出以下評論:“今年的ASCO ,我們遷怒于免疫療法,而首要問題是藥劑成本高到離譜,局面失控。”   MidigitalLife​(追蹤數字醫療保健趨勢的公司)的總經理格雷格(Greg Matthews)對此回復道,“根據初步數據和簡單的關鍵詞,內科醫師發佈的價格是2016年的兩倍。會深入研究。”           ·ASCO公關團隊展示乳腺癌藥物研究   此研究專注於HER2陽性乳腺癌初期患者的組合療法,其新聞報道明確指出組合治療的趨勢。該療法結合一種新藥和一種舊藥——帕妥珠單抗(Perjeta,於2012年獲認證)和曲妥珠單抗(Herceptin,於1998年獲得美國食品及藥物管理局認證)。實驗組的女性能夠服用組合藥物而控制組的女性只服用曲妥珠單抗。       儘管此療法二次阻隔HER2,可能會降低一些女性侵襲性乳腺癌的患病率。但老實說,實驗組和控制組的結果並無太大差別,得出結論應更加謹慎。年會發表了三年後擺脫侵襲性乳腺癌的患者比例,實驗組是94.1%,控制組是93.2%,差距小於1%。   但是研究仍然表明,相比于只服用曲妥珠單抗,組合療法將發展成侵襲性乳腺癌的概率降低了19%。這是描述1%差距的不同方式,也可能會誤導大眾。實驗組和控制組的絕對數值已經徹底描述了1%差距,為什麼為了誇大此藥的微弱療效,還要提出19%的數值?   早期研究還忽略組合療法的副作用,宣稱相比于控制組的患者,實驗組的患者產生嚴重副作用的幾率更低。儘管後來,我們在發表後期了解到,這種說法不適用於心臟衰竭或死於心臟相關疾病(實驗組0.7%;控制組0.3%)和嚴重痢疾(實驗組9.8%;控制組3.7%)。   ·金融媒體反彈   幸運的是,財經新聞媒體反彈。儘管讀者並非目標群眾,仍然向報道有益于病患的新聞。   彭博(Bloomberg)新聞報道——“瑞士羅氏治療乳腺癌的新型組合療法定價過高,但療效幾乎無異於舊藥物”就特別出彩,該報道質疑標題里的效益和文章本身。(報道鏈接:https://www.bloomberg.com/news/articles/2017-06-05/roche-s-pricey-new-breast-cancer-combo-barely-beat-its-old-drug)   “在治療過程中,在曲妥珠單抗(Herceptin)的基礎上,增添瑞士羅氏的新藥帕妥珠單抗(Perjeta)會導致每月6,100美元的花費翻倍,而患者們避免癌症復發幾率會降低1%左右”。   同時,華爾街日報也報道過關於組合藥物的成本、價值及邊緣效益的討論(報道鏈接:https://www.wsj.com/articles/study-questions-value-of-costly-cancer-drug-combinations-1496662202)。   其他網站也有相關報道:   財富雜誌:天價乳腺癌組合藥物療效甚微 瑞士羅氏損失十幾億(報道鏈接:http://fortune.com/2017/06/05/breast-cancer-asco-roche/)   金融時報:瑞士羅氏因組合療法慘遭滑鐵盧(報道鏈接:https://www.ft.com/content/2b87ecbc-4999-11e7-919a-1e14ce4af89b )   福布斯:羅氏藥物微抗乳癌 股市希望渺茫 不敵彪馬(報道鏈接:https://www.forbes.com/forbes/welcome/?toURL=https://www.forbes.com/sites/matthewherper/2017/06/05/roche-drug-keeps-breast-cancer-in-remission-but-tiny-benefit-stokes-hopes-for-smaller-rival-puma/&refURL=https://www.healthnewsreview.org/2017/06/high-drug-costs-stock-values-take-center-stage-final-day-asco/&referrer=https://www.healthnewsreview.org/2017/06/high-drug-costs-stock-values-take-center-stage-final-day-asco/#760fa2204fe7 )     這些報道均面向投資商,重點在於投資利益,而不在於患者利益,有人對此感到不安。     ASCO的一位與會人員——乳腺癌外科醫生兼HealthNewsReview.org作家狄安娜·亞太(Deanna Attai)說,“新聞媒體和其他組織對此研究的報道很有意思。彭博的報道相當全面,多方採訪,梳理子群反應,但是我不太喜歡評論從金融角度撰寫的故事。”   巴西聖保羅BP米蘭特醫院的臨床腫瘤學醫師,里卡多·卡瓦略(Ricardo Carvalho)與她看法相似,在推特上發聲:“在推特上看到腫瘤學研究進展和股票市場獲益的言論,很是心寒,生命的價值本應高於一切。”         我們能體會到,這些新聞報道批判地審查研究結果。記者通常調查不夠深入透徹,只是重複其他新聞報道的觀點,這裡不會發生這種情況,我們認為這是一種小勝利。 https://www.healthnewsreview.org/2017/06/high-drug-costs-stock-values-take-center-stage-final-day-asco/    
張碧瑜 / 癌症資訊網

  【癌症資訊網綜合報道】 每年6月的第一個禮拜,對癌症研究員來說,就意味著美國臨床腫瘤學會的年會。這是全球最盛大的臨床癌症會議,匯集了3萬多名與會人員,包括最傑出的腫瘤學家、各領域中最優秀的科學家、英國癌症研究所(ICR)最拔尖的研究員等。   今年是第53屆ASCO年會,主題是“與你一起改進癌症護理(Making a difference in cancer care with you)”。年會強調,要用更加個性化的方法管理癌症,實現新療法的突破并改善存活率。   ASCO總能成為傳媒焦點,其吸睛能力不亞於英國選舉,今年亦是如此。記者們都渴望報道預防和治療癌症的最新進展,因為這種疾病關係到普羅大眾。     6月2日至6日,ASCO舉辦於美國芝加哥,網絡正流傳主要的會議摘要,而以下是最新研究的摘要,於會議當天發表。無論你正在芝加哥出席此會,還是待在家中對此會議很感興趣,都不會錯過英國癌症研究院發表內容的精彩摘選。其中的一些要點肯定會引發轟動。   ·卵巢癌新藥物 摘要2503:班納吉(Udai Banerji)——英國癌症研究院(ICR)藥物發展部副主任兼皇家馬斯登NHS基金會副會長,主導α-葉酸受體對卵巢癌患者的第一階段試驗,試驗結果將於6月3日發表。   ·阿比特龍(Abiraterone)成首選療法 摘要LBA5003:英國癌症研究院(ICR)對試驗狂潮的結果特別感興趣。阿比特龍由研究院發現并協助研發,這些試驗旨在鑒定阿比特龍融合雄激素阻斷治療的用法,作為前列腺癌晚期患者的首選療法。雖然研究院沒有主導此研究,但是約翰·德博諾教授(Johann de Bono)及同事們均積極參與其中。   ·BRCA成乳腺癌的靶向藥物 摘要LBA4:關注PARP抑制劑Olaparib的3/4階段研究結果,即Olaparib對攜帶BRCA突變體的乳腺癌晚期女性患者的研究。英國癌症研究院(ICR)提出的科學支持PARP抑制劑的發展,PARP抑制劑已對卵巢癌患者和前列腺癌晚期患者均有治療效果,我們非常期待此藥能對其他癌症患者有療效。   ·大規模的肉瘤研究 摘要11004:伊恩·賈德森(Ian Judson)教授和朱迪斯·波利斯(Judith Bliss)教授主導西地尼布(Cediranib)的最大型隨機試驗,涉及英國癌症研究院和皇家馬斯登中肺泡狀軟組織肉瘤患者,發表日期是6月2日。   ·英國癌症研究院(ICR)於芝加哥世界1:15-4:15pm進行內容發佈 摘要1007:尼克·特納(Nick Turner)博士——英國癌症研究院(ICR)分子腫瘤學領導者兼皇家馬斯登醫療腫瘤學顧問,將發表PARP抑制劑talazoparib的第二階段研究結果,即研究攜帶遺傳性BRCA突變體的乳腺癌晚期患者接受鉑或多種化療后,接受talazoparib治療的結果。 摘要5004:哥特·阿塔爾德(Gert Attard)博士——英國癌症研究院(ICR)領導者兼皇家馬斯登顧問,將發表恩雜魯胺(enzalutamide)和阿比特龍(abiraterone)的第四階段試驗結果。該試驗旨在測試接受過恩雜魯胺治療的患者(其前列腺特異抗體在接受恩雜魯胺治療過程中擴展)會受益於以下哪種療法:開始服用阿比特龍乙酸+強的松,同時繼續服用恩雜魯胺;只服用阿比特龍乙酸+強的松。 摘要2506:英國癌症研究院(ICR)和皇家馬斯登藥物研發部的更多研究是新型RAS/MEK抑制劑對攜帶RAS-/RAF-突變癌症的初級試驗研究。     http://icr.ac.uk/blogs/science-talk-the-icr-blog/  
Sy Mukherjee / 翻譯 : 張碧瑜 / 癌症資訊網

【癌症資訊網綜合報道】 6月6日,一年一度的美國臨床腫瘤學會(ASCO)在芝加哥落下帷幕。ASCO年會是臨床腫瘤領域最盛大的會議,匯集了3萬多名腫瘤研究員、生物製藥業的主管、投資商及公共健康專家。   ASCO中,小型生物技術公司還是醫藥巨頭,都有機會展示其對老藥和實驗藥物臨床試驗的最新數據,同時也有論壇討論藥品定價、醫療水平等政策問題。2016年,美國前副總統喬·拜登(Joe Biden)在ASCO發表講話,提出基因組數據共享計劃,促進了癌症研究的發展。   今年年會的三大關鍵點是: ·小公司成年會焦點 早期成果令人驚歎   今年,ASCO的最熱頭條主角大多是小公司,如斯坦福德的CT-based Loxo腫瘤公司(CT-based Loxo Oncology)和中國南京傳奇生物科技公司。Loxo腫瘤公司的最新實驗藥物——Larotrectinib亮相后,其股票價格飆升近50%。76%攜帶某種遺傳標記的患者對此藥產生反應,也就是說,只要患者攜帶該遺傳標記,此藥便能有效對抗大量癌症。而南京傳奇展示了一種新型癌症療法(CAR-T)的早期數據,此療法重建患者的免疫細胞,以抗爭血癌。儘管諾華公司等醫藥巨頭,凱德製藥和朱諾治療公司等著名生物技術公司均立足于此領域,南京傳奇卻憑藉CAR-T搶奪他們的風采,成為年會焦點。CAR-T聚焦各種生物標誌,南京傳奇正在試驗此療法對多發性骨髓癌(一種罕見血癌)的療效。   ·輝瑞斥資140億收購Medivation遭受審查   16年的ASCO中,美國輝瑞斥資140億美元,迅速收購癌症生物技術Medivation,成為最大贏家,其市場價值因此增長20%。此前,Medivation在眾多製藥商中掀起一陣狂熱。製藥商們慾收購這項技術及其前列腺癌療法——恩雜魯胺(Xtandi),其中最出名的是法國賽諾菲。然而,根據ASCO中發表的最新數據,一些分析師懷疑輝瑞為此斥資過多,因為強生研發的療法——阿比特龍(Zytiga)的臨床試驗結果令人印象深刻。一些投資商和醫生預測,阿比特龍將成為前列腺癌高危患者剛確診時的首選。臨床試驗中,阿比特龍為患者降低38%的死亡風險。這意味著,在治療過程中,醫生應盡早為患者開此藥。在過去,恩雜魯胺爭奪強生藥品的市場份額,這樣的趨勢正在逆轉。   ·合並用藥能促進生物製藥交易 將成未來潮流   試驗新一代癌症免疫療法——檢查點抑制劑(如默克公司的Keytruda和百時美施貴寶公司的Opdivo等)和其他癌症療法的組合,是腫瘤研發領域的最大趨勢之一,旨在研發更有療效的合成物,幫助更多癌症患者。研究者正大量進行這類雞尾酒式的臨床試驗,這不僅異於聚焦癌症的生物技術,也是研發主要的檢查點抑制劑的關鍵。   這更能鞏固腫瘤研究領域的發展。生物技術投資商及免疫腫瘤基金經理——布拉德·浪卡爾(Brad Loncar)接受財富雜誌的訪問時表示,“在邏輯上,這是必然趨勢,因為規模更大的醫藥公司必須爭奪另其現有藥物更有效的資源,以提高銷售額。”   http://fortune.com/2017/06/06/cancer-asco-2017-takeaways/        
張碧瑜 / 癌症資訊網

  澳洲每年有1400位女性死於卵巢​癌.  研究者稱,ONX-0801(一種試驗藥物)是卵巢​癌治療領域的重大研究進展。   此藥是過去十年研發中的最大突破。15位患者參加全球首次ONX-0801的臨床試驗,其中7位患者的腫瘤大幅縮減。這些患者預期壽命幾個月,對現存的藥物及治療方案無反應。   更激動人心的是,此藥在攜帶卵巢​癌某致病基因的女性中發揮治療藥效。15位測試者的實驗小組中,10位女性中有7位對ONX-0801有反應。   ONX-0801偽裝成葉酸,進入癌細胞內,抑制胸苷酸合成酶,這是新型藥物的首次嘗試。此研究的負責人Udai Banerji(英國癌症研究所藥物發展部副部長兼倫敦皇家Marsden NHS基金會副會長)表示,“這是全新的作用機制。”   卵巢​癌細胞有異常大量葉酸受體——葉酸受體α,也就是說此療法能有效對抗卵巢​癌細胞。   現存的治療方案對卵巢​癌末期患者無效,而服用ONX-0801,伴有極小的副作用,她們可延長半年多的壽命。Banerji表示,“過去十年,這從未實現。”   倘若後續臨床試驗的結果和首次試驗的結果相似,ONX-0801可能將應用於卵巢​癌初期。Banerji認為,ONX-0801在此階段藥效發揮更佳。   新療法專攻癌細胞,不幹涉健康細胞。這意味著,病患不會遭受化學治療帶來的副作用,如感染、腹瀉、神經損傷及掉髮等。   研究者也創建了測試,探測對ONX-0801反應最敏感的細胞。也就是說,醫生能夠識別接受此藥物治療獲益最大的那群女性。Banerji表示,“當然,現在為時尚早,我非常期待這個療法的後期臨床試驗。”   卵巢​癌的症狀較模糊,很多患者求醫時,已是癌症晚期。約60%的女性確診時,癌細胞已擴散至全身,無法治愈。   癌症協會的報告指出,在澳洲,僅44%的卵巢​癌患者在確診后能存活5年。卵巢​癌症狀包括: 腹脹;食欲不振或很快有飽腹感;尿頻或尿急;背部、腹部或骨盆疼痛;便秘;月經失調;疲憊;消化不良;性行為期間疼痛等。   關於卵巢​癌的更多信息,請訪問澳洲癌症協會官網  http://www.cancer.org.au/about-cancer/types-of-cancer/ovarian-cancer.html   Full coverage   Biggest ovarian cancer breakthrough in a decade hailed by researchers The Independent - ‎Jun 2, 2017‎ Experts called results of the early-phase study “exciting” and “promising” after patients who had exhausted all other treatment options showed an impressive response. The drug, known as ONX-0801, was tested in 15 women with advanced ovarian cancer as ...   Experimental ovarian cancer treatment looks 'very promising', researchers say The Guardian - ‎Jun 2, 2017‎ An experimental new treatment for ovarian cancer led to a dramatic shrinking of tumors in a small, early-phase study. Researchers were testing a drug, known as ONX-0801, for safety, but found that tumors in half of the 15 women studied shrank during ...   'Biggest breakthrough in 10 years' in treatment of ovarian cancer Mirror.co.uk - ‎Jun 2, 2017‎ Scientists have made the biggest breakthrough in a decade in the treatment of advanced ovarian cancer . Seven out of 15 women taking new drug ONX-0801 in a trial run by London's Royal Marsden Hospital were told their tumours had shrunk dramatically.   ASCO 2017: Ovarian cancer drug delivers 'very promising' results in early trial The Institute of Cancer Research - ‎Jun 2, 2017‎ A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the drug, known in the study as ONX-0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial. Phase I trials are run in ...   Ovarian cancer drug hailed as 'biggest breakthrough in a decade' Sky News - ‎Jun 2, 2017‎ The trial was part of a larger study by the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust in London. ONX-0801 enters the cancer cells by mimicking folic acid - ovarian cancer has a large number of receptors for folic acid.   Researchers hail 'breakthrough' drug for treating ovarian cancer The New Daily - ‎Jun 3, 2017‎ Researchers are hailing an experimental drug as a major advance in the treatment of ovarian cancer, which typically claims the lives of up to 1400 Australian women every year. The drug, known as ONX-0801, is being described as the biggest breakthrough ...   Drug shrinks ovarian tumours in early trial BBC News - ‎Jun 2, 2017‎ NHS Choices: Ovarian cancer. The researchers, from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in London, wanted to establish whether the drug, known in the study as ONX-0801, was safe, so they tested it on a small ...   'Biggest breakthrough in a decade': New ovarian cancer drug proves hugely promising RT - ‎Jun 3, 2017‎ The trial also found that because ONX-0801 targets cancer cells specifically, while leaving healthy cells alone, patients did not experience common side effects such as infections, diarrhoea, nerve damage and hair loss associated with traditional ...   Scientists make 'biggest breakthrough in ovarian cancer for 10 years' Evening Standard - ‎Jun 3, 2017‎ Cancer patients who had run out of other options responded well to the new drug in a medical advance which experts have hailed as “exciting” and “promising”. The drug – called ONX-0801 – was tested on 15 woman with advanced ovarian cancer in the first ...   Cancer patient hails 'highly promising' new treatment after tumours shrink ITV News - ‎Jun 3, 2017‎ A new treatment for ovarian cancer has been hailed "highly promising" by researchers after it was found to significantly shrink tumours. Seven out of 15 women with advanced ovarian cancer, who had exhausted all other treatment options, saw their ...   Groundbreaking new drugs give months of extra life for women suffering from ovarian cancer Telegraph.co.uk - ‎Jun 2, 2017‎ Current efforts to combat the ovarian cancer mainly focus on targeted therapies which try to match interventions with certain gene types. But researchers say the new ONX-0801 drug has could be of benefit a wide cohort of women with advanced ovarian ...   This Could Be The Biggest Breakthrough In Treating Ovarian Cancer For A Decade Refinery29 - ‎Jun 3, 2017‎ ONX-0801 works by mimicking folic acid to enter the cancer cells, and then killing them by halting the action of a protein called hymidylate synthase. Because it targets cancer cells specifically, it carries none of the side effects associated with ...   Ovarian cancer drug shrinks tumours in trials The Times (subscription) - ‎Jun 2, 2017‎ Only one in three women with the cancer will survive for more than ten years and it causes 4,000 deaths a year in Britain. Scientists at the Institute of Cancer Research have developed a compound, ONX-0801, that sneaks into the tumour by disguising ...   New drug shrinks ovarian tumors in early trial kwbe - ‎Jun 3, 2017‎ (CHICAGO) — A new treatment for ovarian cancer has shown “promising” results in women who are in the advanced stages of the disease, according to the BBC. The drug, known as ONX-0801, shrunk tumors in more than half the patients who participated in ...   Scientists develop new targeted ovarian cancer treatment with no side effects AppsforPCdaily - ‎Jun 3, 2017‎ The team tested the drug, ONX-0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial. The drug had significantly shrunk tumors in seven of the patients who carried the specific molecule that the drug was created to target. Her ...  
作者 : Helen Law / 癌症資訊網 ( 综合報導 )

  治癌藥物首重基因而非腫瘤位置   免疫治療是癌症治療的突破,更多患者將因此而得益。   就精準醫療而言,一種治療癌症的藥物首次得到監管機構的批准。該藥物的機制是根據腫瘤的基因特徵,而非腫瘤在體內的位置。   2017年​5月​23日​,美國食品和藥物管理局(FDA)表示已批准一種免疫療法藥物Keytruda,用於所謂「錯配修復」基因導致的遺傳性疾病的患者。   這些基因突變意味著它們的細胞不能完全修復DNA在生長和分裂過程中出現的錯誤,這可能引發癌症,這類腫瘤對由Merck銷售的Keytruda反應特別理想 。   FDA藥物評估及研究中心的血液及腫瘤學產品辦公室署理總監Richard Pazdur在一份聲明中稱,該批准是「癌症群體中最重要的進展」。   精準醫療的意念是根據別患者的基因特徵及其他相關資訊,來擬訂個人化的治療方法。然而,迄今為止,癌症的治療一直根據腫瘤的所在位置,例如乳腺癌或肺癌。   Keytruda是第一種藥物,可以給予同時擁有兩個相對罕見的異常基因,並且患有實體腫瘤的人,例如胰腺癌或肺癌患者。 一家諮詢公司Bionest Partners的執行合夥人Olivier Lesueur稱,這個批准是「我們所見定義癌症的方式的突破」。   Keytruda透過啟動人體的免疫系統來攻擊腫瘤,並於2014年首次被批准用於治療晚期皮膚癌。這種稱為「檢查點抑制劑」的藥物取得了顯著的成功,包括挽救了前美國總統Jimmy Carter的生命。然而,免疫治療的缺點是,似乎並非所有患者都能得益,其原因尚不明確。   隨著FDA的核准,預期能得益的患者人數可能會大幅增長。約翰霍普金斯大學彭博金梅爾免疫治療研究所的腫瘤學家Dung Le說,約有4%的晚期癌症患者 - 美國一年多達30,000名患者 - 帶有Keytruda能夠治療的異常基因。   「這種藥物可以幫助到一些我們以前無法提供治療的患者。」Dung Le說。   Keytruda僅適用於接受傳統治療(如化療)失敗的患者。但是,Dung Le認為基因檢測可以廣泛地使用於確定異常基因,費用在300至600美元之間,而Keytruda 的費用約為每年15萬美元。   約翰霍普金斯大學醫院和其他四所醫院進行一項臨床試驗,涉及149名患有15種不同類型癌症的患者。在該試驗中,約40% 患者的腫瘤完全消失或明顯縮小。這使Merck的申請獲得「加速」批准。 其中一名患者Adrienne Skinner,60歲,來自紐約州Larchmont。她在2013年被診斷患有晚期壺腹癌(一種罕見且致命的胃腸癌)後,經歷了一年的化療。   2014年4月,Skinner參加了Keytruda臨床研究。她是一名候選人,因為她一出生便患有遺傳性的Lynch Syndrome,其DNA修復基因無法正常地工作。 在參加Keytruda臨床研究的短短幾個月裡,一名外科醫生為她檢查,並告訴她體內的腫瘤已經消失了。   Skinner繼續服用Keytruda兩年,並表示她現在覺得自己回復正常了。她現時有全職工作,常常到健身房、打網球、做瑜伽。她說:「如果沒有Keytruda的出現,我已離開了這個世界。」   FDA News Release https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm     Keytruda Granted Priority Review for Advanced Gastric Cancer Curetoday.com - ‎May 25, 2017‎ Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses ...     Keytruda Approved for Any Solid Tumor With a Specific Genetic Marker Curetoday.com - ‎May 23, 2017‎ Keytruda (pembrolizumab) was granted an accelerated approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients who have unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch ...   Mutation over location for new Keytruda approval BioWorld Online - ‎May 24, 2017‎ Keytruda (pembrolizumab, Merck & Co. Inc.) has become the first drug to be approved based solely on the presence of a molecular biomarker without regard to tumor location. The tissue agnostic approval "for the treatment of adult and pediatric patients ...   FDA Chalks Up a First by Approving Keytruda for Cancers with Specific Genetic Features Immuno-Oncology News - ‎May 25, 2017‎ In a first, the U.S. Food and Drug Administration has approved a treatment for cancer patients with specific genetic features in their tumors rather than a specific tumor type. The approval, based on clinical trial results of Merck's Keytruda ...   FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects Wall Street Journal (subscription) - ‎May 23, 2017‎ The U.S. Food and Drug Administration on Tuesday approved Merck & Co.'s Keytruda drug to treat tumors with a certain genetic defect—the first time the agency has cleared a cancer drug for a use not tied to the site of a tumor. The FDA approved ...   Merck's Keytruda gets first nod in genetically-defective tumors BioPharma Dive - ‎May 24, 2017‎ Merck's Keytruda (pembrolizumab) notched a first-of-its-kind victory on Tuesday, getting accelerated approval from the Food and Drug Administration as a treatment for tumors that demonstrate an uncommon mutation affecting the way in which they fix ...   FDA clears Merck's Keytruda based on cancer genetics, not location Reuters - ‎May 23, 2017‎ Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated. The approval marks ...   US approves Keytruda for MSI-H tumours PharmaTimes - ‎May 24, 2017‎ The US Food and Drug Administration has cleared use of Merck & Co's immunotherapy Keytruda to treat cancer patients identified as having a biomarker called microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Microsatellite ...   Fresh off two new FDA nods, Merck's high-flying Keytruda nets priority status in stomach cancer FiercePharma - ‎May 23, 2017‎ In a month that's featured three FDA approvals for Keytruda, the immuno-oncology med has netted a speedy review for the therapy in stomach cancer. On Tuesday, U.S. regulators bestowed their priority tag on the Merck drug, hastening their review of the ...   Keytruda wins another first with approval based on biomarkers pharmaphorum - ‎May 24, 2017‎ Merck & Co has notched up another first with Keytruda, the FDA approving the drug for use against solid tumours anywhere in the body which express a certain genetic features. This is the first time any drug has been approved on its genetic profile ...     Merck's Keytruda wins first FDA nod to treat genetically ID'd tumors anywhere in the body FiercePharma - ‎May 23, 2017‎ Keytruda's other indications—in bladder cancer and lung cancer, for instance—depend upon the part of the body where a tumor originated. This time, Keytruda won a go-ahead to treat any solid tumor in any part of the body, as long as it bears specific ...     FDA Grants Priority Review to Keytruda for Heavily-treated Stomach Cancer Patients Immuno-Oncology News - ‎May 24, 2017‎ The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Licence Application (sBLA) seeking approval for Keytruda (pembrolizumab) to treat patients with recurrent or advanced gastric or gastroesophageal junction ...   Latest Keytruda approval a milestone for precision oncology The Pharma Letter (registration) - ‎May 24, 2017‎ America's Merck & Co (NYSE: MRK) has received yet another US FDA approval, the second in as many weeks, for its immuno-oncology drug Keytruda (pembrolizumab). In something of a regulatory milestone for the agency, the drug has been indicated for ...     In Bold Move, FDA Approves Cancer Drug For Any Advanced Tumor With Genetic Changes Forbes - ‎May 23, 2017‎ For the first time, the FDA has approved a drug for use in cancer—of any type—that harbors certain molecular features. Merck's Keytruda, an immune oncology drug, may be prescribed for any resistant, metastatic tumor with microsatellite instability ...   Groundbreaking clinical trial drug leaves Duarte man cancer-free KABC-TV - ‎May 25, 2017‎ Seven months after bladder cancer patient Maurice Ray underwent a clinical trial for the immunotherapy drug Keytruda, he is now cancer free. (KABC). KABC. By Denise Dador. Thursday, May 25, 2017 10:19AM. DUARTE, Calif. (KABC) --. Seven months after ...
Alan Ng / 癌症資訊網

  美國食品和藥物管理局(FDA)於2017年4月25日向非法銷售欺騙聲稱可以預防、診斷、治療或治愈癌症的超過65項產品的14家美國公司發布了警告信。這類產品的營銷和銷售均未經 FDA的批準,最常見的的是在網站上或者在社交媒體平台上銷售。    “消費者不應該使用這些產品或者類似的未經證實的產品,因為它們可能不安全,不可能阻止人們尋求適當的和可能拯救生命的癌症診斷或治療,”FDA 監管事務辦公室的執法和進口業務辦公室主任Douglas W. Stearn表示。“我們鼓勵人們保持警覺,無論是在線還是在商店,並且避免購買沒有證據證明有效的治療癌症的產品。患者應該向他們的醫療保健專業人員咨詢癌症的適當預防、診斷和治療事項。”   在沒有首先向FDA 證明其產品安全和對標示的用途具有功效的情況下營銷和銷售聲稱可以預防、診斷、治療、減輕或治愈疾病的產品,這是違反《聯邦食品、藥物和化妝品法案》的。今天發布的警告信中列出的非法銷售的產品種類眾多,如糖丸、外用藥膏、藥膏、油、點滴、糖漿、茶和診斷器材(如熱成像設備)。它們包括營銷供人和寵物使用的產品,這項產品在預防、逆轉或治愈癌症、殺死/抑制癌細胞或腫瘤方面做出了非法和未經證明的聲明,或者其他類似的抗癌聲明。   FDA 已經要求這14家公司回應,說明如何糾正違規。如果沒有立即糾正違規,則可能導致法律行動,包括扣押產品、禁令及/或刑事起訴。   作為FDA 保護消費者免遭癌症保健欺詐工作的一部分,FDA 在過去的10年已經發出了超過 90 封警告信,警告在網站、社交媒體和商店中營銷聲稱治療癌症的數以百計的欺詐產品的公司。雖然其中的許多公司停止了銷售產品或者做出欺詐性聲稱,部分由於公司可以輕鬆地把營銷業務搬遷到新的網站的原因,許多不安全和未經批準的產品繼續直接售給消費者。FDA繼續監視促銷和銷售未經證明的治療產品的公司,並且針對他們采取行動,旨在把對消費者的潛在危險減到最小,並且教育消費者了解這些風險。   FDA鼓勵醫療保健專業人員和消費者向該機構的 MedWatch https://www.fda.gov/Safety/MedWatch 程序舉報與這些產品或類似產品相關聯的不良反應。   了解更多信息: FDA健康欺詐信息 https://www.fda.gov/ForConsumers/ProtectYourself FDA 的警告信 https://www.fda.gov/ICECI/EnforcementActions 假癌癥治療的列表 https://www.fda.gov/ForConsumers/ProtectYourself 常見問題 – 假癌癥治療 https://www.fda.gov/ForConsumers/ProtectYourself 消費者更新 – 癌癥欺詐:殘酷的欺騙 https://www.fda.gov/ForConsumers/ConsumerUpdates     FDA是美國衛生及公共服務部的一個機構。該機構通過確保人類和獸用藥物、疫苗和其他用於人類的生物產品和醫療器械的安全、有效和保障來保護公眾健康。該機構還負責美國的食品供應、化妝品、營養補充品、發出電子輻射的的產品的安全和保障,並且監管煙草制品。   Full coverage   FDA Issues Warning Over 65 Fraudulent Cancer Treatments Curetoday.com - ‎Apr 25, 2017‎ This week, the Food and Drug Administration (FDA) issued 14 warning letters and four online advisories to companies that claim to prevent, diagnose, treat, mitigate or cure cancer. The letters cover over 65 products that were being sold — mostly on ...   Press Announcements > FDA takes action against 14 companies for ... FDA.gov - ‎Apr 25, 2017‎ The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that ...   FDA: Avoid fake 'miracle' cancer treatments sold on internet ABC News - ‎Apr 25, 2017‎ FILE - This Wednesday, Oct. 14, 2015, file photo shows the U.S. Food and Drug Administration campus, in Silver Spring, Md. The FDA is warning consumers to avoid 65 bogus products hawked on the internet with false claims that they can cure, treat or ...   FDA: Avoid 65 bogus 'miracle' cancer products sold on internet PhillyVoice.com - ‎Apr 25, 2017‎ TRENTON, N.J. — U.S. regulators are warning consumers to avoid 65 bogus products hawked on the internet with false claims that they can cure, treat, diagnose or prevent cancer. The Food and Drug Administration says these products , mostly sold on ...   FDA cracks down on 'illegal' cancer treatments CNN - ‎21 hours ago‎ On Tuesday, the agency responsible for policing the American food and drug market issued warning letters to 14 companies that it says are "illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer ...   FDA Takes Action Against 'Bogus Cancer Cures' Medscape - ‎Apr 25, 2017‎ "Today we are announcing that 14 companies peddling bogus cancer cures have received warning letters," write physicians at the US Food and Drug Administration (FDA) in a blog post. "A cancer diagnosis often provokes a sense of desperation," they write.   FDA warns 14 companies about fake cancer 'cure' products UPI.com - ‎Apr 25, 2017‎ TUESDAY, April 25, 2017 (HealthDay News) -- The U.S. Food and Drug Administration on Tuesday posted warning letters to 14 companies that are selling more than 65 fake cancer treatments. The bogus products include pills, capsules, powders, creams, ...   FDA cracks down on sham 'miracle' cancer treatments Fox News - ‎4 hours ago‎ The letters, detailed Tuesday on the agency's website, addressed more than 65 products currently marketed and sold without FDA approval. CHILI PEPPER, POT MAY FIX YOUR AILING STOMACH. “Anyone who suffers from cancer, or knows someone who ...   14 Companies Illegally Selling Cancer Drugs Receive FDA Warning Letters Pharmacy Times - ‎Apr 25, 2017‎ Over the past decade, the FDA has issued more than 90 warning letters to companies marketing hundreds of fraudulent products that made unfounded cancer claims. Although most of the companies have stopped selling these products, there are still unsafe ...   FDA names 14 'cruel' companies pedaling 'cancer cures' Daily Mail - ‎Apr 25, 2017‎ Across the 14 firms, investigators identified 65 products that claim to cure or treat cancer. They include teas that claim to be made from 'cancer-killing trees', and capsules that promise to fight cancer - as well as Parkinson's disease, heart disease ...   The FDA Just Cracked Down on 14 Companies Selling Fake Cancer Treatments Gizmodo - ‎Apr 25, 2017‎ BioStar Organix is one among 14 companies that the FDA is cracking down on for illegally selling more than 65 pills, creams, ointments, oils and other products that fraudulently claim to prevent, diagnose, treat or cure cancer in humans and pets.   FDA cracks down on bogus cancer treatments CBS News - ‎2 hours ago‎ Yesterday, the agency issued warning letters to 14 U.S.-based companies peddling more than 65 of these bogus cancer cures. The products are marketed and sold without FDA approval, most commonly on websites and social media platforms. “Consumers ...
Neowin / Play Store

  英國倫敦大學國王學院醫院,推出了一款面向核磁共振成像掃描(MRI)的虛擬現實(VR)應用。這款由醫學博士 Jonathan Ashmore 和學習專家 Jerome Dipereo 設計的免費 app,展示了 360° 的核磁共振成像掃描的流程體驗,旨在減輕患者(特別是孩子們)在做檢查之前的恐懼。感興趣的網友們可以到 Google Play 下載。 通過虛擬現實的方式,這款應用可以帶著你游覽一家醫院,使用者可以摁下導航按鈕,在不同的大樓見穿梭(比如休息室和 MRI 手術室等)。 隨後,醫生會過來問候患者,在掃描開始前解釋相關醫療流程。     一位 10 歲的小朋友(Matthew Downe)說到:“我想這可以讓孩子們平靜下來,如果他們變得有些激動的話… 這款應用能夠讓你看到周邊的環境,在真實掃描之前感受體驗… 是一種不錯的准備方式”。         UK hospital uses VR to reassure children before MRI scans Engadget - ‎Feb 17, 2017‎ To help patients, and in particular children, the Kings College Hospital in London has turned to VR. MRI physicist Jonathan Ashmore and technologist Jerome Di Pietro have produced an app that contains a 360-degree video. Slip on a Google Cardboard and ...   UK hospital uses VR to ease kids' nerves before an MRI The Verge - ‎Feb 17, 2017‎ The Kings College Hospital in London this week launched an Android app to be used with virtual reality headsets such as the Google Cardboard. In it, kids can look around the room in 360-degree view and listen as the video explains what to expect when ...   VR app helps prepare children for MRI New Atlas - ‎Feb 17, 2017‎ An MRI physicist at King's College Hospital in London has spearheaded a virtual reality app to help soothe children's fears about receiving an MRI. The "My MRI at King's" app is specially designed to walk children through the MRI process, which can be ...   British hospital uses VR to make MRI less scary for kids TNW - ‎Feb 17, 2017‎ King's College Hospital teamed with one of the hospital's play specialists to create an app that — when worn before an MRI — helps kids understand the procedure through an immersive VR experience.   UK hospital uses 360-degree video to reassure kids ahead of MRI scans Digital Trends - ‎Feb 17, 2017‎ However, these technologies can also be used to give people a preview of something they're going to experience in real life, as evidenced by a project being implemented at King's College Hospital in London, England. MRI physicist Jonathan Ashmore ...   This VR app helps children get prepared for an MRI The TechNews - ‎Feb 18, 2017‎ In order to help the children, MRI physicist Jonathan Ashmore and Jerome Di Pietro, a Learning Technologist at King's College London have developed an app. Named My MRI at King's, this app contains a 360-degree video that lets children experience the ...
chanleungcho
dr.chan
breasthk
immuno
免疫營養
藥物資助
講座活動
聯絡電話:
2121 1328
聯絡地址:
Flat B, 8/F., Mow Hing Industrial Building, No.205 Wai Yip Street,
Kwun Tong, Kowloon, Hong Kong
香港觀塘偉業街205號,
茂興工業大廈8樓B室

聯絡地址:
Flat B, 8/F., Mow Hing Industrial Building,
No.205 Wai Yip Street, Kwun Tong,
Kowloon, Hong Kong
香港觀塘偉業街205號,
茂興工業大廈8樓B室
聯絡電話:
2121 1328

聯絡電郵:
info@cancerinformation.com.hk

會員註冊 | 私隱政策 | 服務條款
版權所有 不得轉載 © Copyright 2013 Cancer - information Co. All rights reserved. Powered by BIC Online